A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation with SMT C1100 in Ambulatory Paediatric Male Subjects with Duchenne Muscular Dystrophy (C11005)

Trial Profile

A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation with SMT C1100 in Ambulatory Paediatric Male Subjects with Duchenne Muscular Dystrophy (C11005)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Ezutromid (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Pharmacokinetics; Proof of concept; Therapeutic Use
  • Acronyms PhaseOut DMD
  • Sponsors Summit Therapeutics
  • Most Recent Events

    • 20 Nov 2017 According to a Summit Therapeutics media release,with the completion of the 24-week dosing, company is expecting report results from initial 24-week dosing period in the first quarter of 2018, and complete 48-week data in third quarter of 2018.
    • 09 Nov 2017 According to a Summit Therapeutics media release, this trial will be presented at the 15th Action Duchenne International Conference 2017.
    • 04 Oct 2017 According to a Summit Therapeutics media release, baseline characteristics of patients enrolled in this trial will be presented at the 22nd International Congress of the World Muscle Society. Top-line data from the complete 48-week clinical trial are expected in Q3 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top